Biotech News Alert: GenSpera (OTCQB:GNSZ) Receives Patent on
Prodrug Targeted for Prostate Cancer
SAN ANTONIO - September 9, 2014 (Investorideas.com Biotech
Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for
the treatment of cancer, today announced that the United States Patent and
Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated
Prodrugs."
The
patent covers the composition of a specific prodrug activated by Prostate
Specific Antigen (PSA) that is designed to deliver a thapsigargin derivative
selectively to prostate cancers. PSA is an enzyme secreted by prostate cancer
cells. A derivative of thapsigargin, 12ADT, is the active component of mipsagargin
(G-202), GenSpera's lead drug candidate in Phase II clinical trials for
glioblastoma (brain cancer) patients and for hepatocellular carcinoma (liver
cancer) patients after sorafenib (Nexavar®) therapy. GenSpera currently owns or
licenses 13 issued patents overall with 10 relating to prostate cancer.
"The issuance of this patent further
strengthens our intellectual property position for targeted anti-cancer
prodrugs and recognizes their unique applicability in treating prostate
cancer," commented GenSpera CEO, Craig Dionne, PhD "Each year over
230,000 men are diagnosed with prostate cancer in the United States alone and
approximately 30,000 men die of the disease. The market for prostate cancer
drugs is estimated to be $6.7 billion by the year 2020. Current treatment
options are dominated by drugs that work via chemical castration of the
patient. It is important that we develop safe and effective drugs for these men
without the very significant side effects of current treatments."
Read this release
in full at http://www.investorideas.com/CO/GNSZ/news/2014/09091.asp
About GenSpera
GenSpera's
technology platform combines a powerful, plant-derived cytotoxin (thapsigargin)
with a prodrug delivery system that provides for the targeted release of drug
candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin
results in cell death irrespective of the rate of cell division, which may
provide an effective approach to kill both fast- and slow-growing cancers.
GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA,
which is found at high levels in the vasculature of liver and glioblastoma
cancers and in the vasculature of almost all other solid tumors. Mipsagargin is
therefore expected to have potential efficacy in a wide variety of tumor types.
Mipsagargin
Phase II clinical trials are underway in both hepatocellular carcinoma and
glioblastoma patients.
For
more information, please visit the company's website: www.genspera.com or follow us on
Twitter @GenSperaNews.
Cautionary Statement Regarding
Forward Looking Information
This
news release may contain forward-looking statements. Investors are cautioned
that statements in this press release regarding potential applications of
GenSpera's technologies constitute forward-looking statements that involve
risks and uncertainties, including, without limitation, risks inherent in the
development and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need for future
capital, dependence upon collaborators and maintenance of our intellectual
property rights. Actual results may differ materially from the results
anticipated in these forward-looking statements. Additional information on
potential factors that could affect our results and other risks and
uncertainties will be detailed from time to time in GenSpera's periodic reports
filed with the Securities and Exchange Commission.
CONTACT:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc. (210) 479-8112
Investors:
Steve
Gersten
Capital
Markets Group
Steve@CapMarketsGroup.com
+1-813-926-8920
Media:
Dawn
Van Zant
(800)
665 0411
Disclaimer/Disclosure: Investorideas.com
newswire is a third party publisher of news and research as well as creates
original content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of
stocks or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged
Investor Ideas for PR and news publication effective June 18, 2014 (compensation
of five thousand per month and average of eleven thousand five hundred 144
shares per month)
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 –biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
No comments:
Post a Comment